TY - JOUR
T1 - Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy
AU - Sonpavde, Guru
AU - Aparicio, Ana
AU - Guttierez, Israel
AU - Boehm, Kristi A.
AU - Hutson, Thomas E.
AU - Berry, William R.
AU - Asmar, Lina
AU - Von Hoff, Daniel D.
N1 - Funding Information:
This study was sponsored by Pharmion Corp, Boulder, CO.
PY - 2007/12
Y1 - 2007/12
N2 - Epigenetic alterations, including methylation of key tumor suppressor genes, may play a role in the progression of prostate cancer to a castration-refractory state. Azacitidine, an agent approved for the treatment of myelodysplastic syndromes, appears to exert its antineoplastic effects partly by hypomethylating DNA that leads to the reversal of gene silencing. It is hypothesized that the addition of azacitidine to complete androgen blockade may restore the responsiveness of progressive prostate cancer to hormonal therapy. A phase II trial was designed to evaluate the activity of azacitidine to primarily modulate PSA kinetics, with supportive secondary clinical endpoints. Correlative studies will be performed to detect the biologic activity of azacitidine (increased fetal hemoglobin, plasma DNA methylation) and examine any association with anti-tumor clinical activity.
AB - Epigenetic alterations, including methylation of key tumor suppressor genes, may play a role in the progression of prostate cancer to a castration-refractory state. Azacitidine, an agent approved for the treatment of myelodysplastic syndromes, appears to exert its antineoplastic effects partly by hypomethylating DNA that leads to the reversal of gene silencing. It is hypothesized that the addition of azacitidine to complete androgen blockade may restore the responsiveness of progressive prostate cancer to hormonal therapy. A phase II trial was designed to evaluate the activity of azacitidine to primarily modulate PSA kinetics, with supportive secondary clinical endpoints. Correlative studies will be performed to detect the biologic activity of azacitidine (increased fetal hemoglobin, plasma DNA methylation) and examine any association with anti-tumor clinical activity.
KW - Androgen-deprivation therapy
KW - Myelodysplastic syndrome
KW - Prostate-specific antigen
UR - http://www.scopus.com/inward/record.url?scp=38949164700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38949164700&partnerID=8YFLogxK
U2 - 10.3816/CGC.2007.n.036
DO - 10.3816/CGC.2007.n.036
M3 - Article
C2 - 18272030
AN - SCOPUS:38949164700
SN - 1558-7673
VL - 5
SP - 457
EP - 459
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 7
ER -